- Home
- / Vanda Pharmaceuticals
Vanda Pharmaceuticals
Stock Price
$4.7
2024-10-29
Market Capitalization
$273.4 M
2024-10-29
Revenue
$216.1 M
FY, 2025
Vanda Pharmaceuticals Summary
Company Summary
- Overview
- Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder, and Fanapt (iloperidone), a product for the treatment of schizophrenia. The Company also has several clinical development products.
- Type
- Public
- Status
- Active
- Founded
- 2002
- HQ
- Washington, DC, US | view all locations
- Website
- http://www.vandapharma.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Anne Sempowski Ward, Director
Mihael H. Polymeropoulos, President, Chief Executive Officer and Chairman of the Board
Gunther Birznieks, Senior Vice President, Business Development
LocationsView all
3 locations detected
Washington, DC HQ
United States
The Avenue, 2200 Pennsylvania Ave NW #300E
Berlin, Berlin
Germany
Französische Straße 12 c/o Satellite Office
London, England
United Kingdom
Tower 42, 21st Floor, 21A 25 Old Broad Street
Vanda Pharmaceuticals Financials
Summary Financials
- Revenue (Q1, 2026)
- $51.7M
- Net income (Q1, 2026)
- ($48.6M)
- Cash (Q1, 2026)
- $54.0M
- EBIT (Q1, 2026)
- ($50.2M)
- Enterprise value
- $226.4M